Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY “Comprehensive Strategy” Updated after 2 Years, MHLW to Mull Procedures for Info Handover for Brand-Name Meds Bowing Out of Market
December 25, 2017
-
ORGANIZATION JPMA to Call for Improvements in PMP-Eligibility Criteria, Company Requirements: Chief
December 22, 2017
-
REGULATORY Chuikyo OKs Drug Pricing Reform Package; 30% Cap Set for “Category I” Companies Allowed to Maintain Full Prices
December 21, 2017
-
BUSINESS GSK Japan Pres. Kikuchi to Quit after Only 9 Months in Office
December 20, 2017
-
BUSINESS Gilead Aiming to Develop World’s First NASH Treatment, Hoping for Approval in 2020
December 20, 2017
-
REGULATORY (Update) Japan to Shave 720 Billion Yen through FY2018 Drug Price Revision
December 19, 2017
-
REGULATORY Govt to Draw Up “Plan to Strengthen Drug Discovery,” Boosting Budgets to Improve R&D Environment
December 18, 2017
-
BUSINESS Partnerships Hold Key to Success, Acquisition Not Our Goal: Takeda R&D Head
December 15, 2017
-
REGULATORY Chuikyo Debate Intermitted as Members Fume at Political Arrangement, New PMP Plan Still Clears Panel with Strings Attached
December 14, 2017
-
REGULATORY Chuikyo Members Snub Possible Change to 14-Day Prescription Limit
December 13, 2017
-
BUSINESS Japan Drug Makers Driven by Overseas Sales, See Tepid Revenue at Home: Jiho Tally
December 12, 2017
-
REGULATORY MHLW Proposes Physician Fee for Proper Antibiotic Use in Children, Aims to Cut Unnecessary Use: Chuikyo
December 11, 2017
-
BUSINESS AbbVie Hopes Maviret Will Encourage Potential Hep C Patients to Get Treatment: Hepatitis Biz Head
December 11, 2017
-
REGULATORY Govt’s Modified PMP Plan: “1-Year Cutoff” Extended for 3 Years, 25% of Firms Could Now Maintain Full Prices
December 8, 2017
-
REGULATORY Easing of Proposed PMP Requirements Likely, Major Focus on “One-Year Cutoff” and “Category I” Scope
December 7, 2017
-
REGULATORY (Update) NHI-Market Drug Price Gap at 9.1%, 7.1% Regular Price Cut Expected in FY2018
December 6, 2017
-
REGULATORY NHI-Market Drug Price Gap at 9.1%, 7.1% Regular Price Cut Expected in FY2018
December 6, 2017
-
REGULATORY Novo’s Semaglutide Stumbles as Panel Puts a Hold on Japan Approval
December 5, 2017
-
REGULATORY CEFP Members Want Quicker Cuts for Off-Patent Drugs, Pricing Debate Enters Final Stretch
December 4, 2017
-
BUSINESS Ayumi Looks to Haul in Over 10 Billion Yen from 3 RA Biosimilars: President
December 1, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…